Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2020

Open Access 01-12-2020 | Urokinase | Research Letter

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

Authors: Nikoletta Rovina, Karolina Akinosoglou, Jesper Eugen-Olsen, Salim Hayek, Jochen Reiser, Evangelos J. Giamarellos-Bourboulis

Published in: Critical Care | Issue 1/2020

Login to get access

Excerpt

As of April 1, 2020, 885,689 cases of infections by the novel coronavirus SARS-CoV-2 (COVID-19) have been recorded worldwide; 44,217 of them have died (https://​www.​worldometers.​info/​coronavirus). At the beginning of the illness, patients may experience low-degree fever or flu-like symptoms, but suddenly, severe respiratory failure (SRF) emerges [1]. Increased circulating levels of D-dimers [1, 2] suggest endothelial activation. Urokinase plasminogen activator receptor (uPAR) that is bound on the endothelium may be cleaved early during the disease course leading to an increase of its soluble counterpart, namely suPAR [3]. If this holds true, then suPAR may be used as an early predictor of the risk of SRF. …
Literature
1.
2.
Pixley RA, Espinola RG, Ghebrehiwet B, Joseph K, Kao A, Bdeir K, et al. Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore). Thromb Haemost. 2011;105:1053–9.CrossRef
3.
Schultz M, Rasmussen LJH, Høi-Hansen T, Kjøller E, Jensen BN, Lind MN, et al. Early discharge from the emergency department based on soluble urokinase plasminogen activator receptor (suPAR) levels: a TRIAGE III substudy. Dis Markers. 2019;2019:3403549.CrossRef
4.
Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382:416–26.CrossRef
5.
Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I, Dimopoulou I, et al. Risk assessment in sepsis: a new prognostication score by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012;16:R149.CrossRef
6.
Metadata
Title
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
Authors
Nikoletta Rovina
Karolina Akinosoglou
Jesper Eugen-Olsen
Salim Hayek
Jochen Reiser
Evangelos J. Giamarellos-Bourboulis
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2020
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-020-02897-4

Other articles of this Issue 1/2020

Critical Care 1/2020 Go to the issue

Letter

COVID-19 pandemic, healthcare providers’ contamination and death: an international view

Letter

High-frequency oscillatory ventilation for PARDS: awaiting PROSPect

Research Letter

Mortality rate of acute kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and meta-analysis

Research

Effect of antiviral therapy on the outcomes of mechanically ventilated patients with herpes simplex virus detected in the respiratory tract: a systematic review and meta-analysis

Editorial

How I approach weaning from venoarterial ECMO

Correction

Correction to: Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia